A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies

Contact:

212-342-5162

NCT Number:

NCT04104672

Protocol:

AAAS7260

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I

This study is being done to see if potential new drugs, AB680 and AB122, can be safely given in combination with chemotherapy to study patients with pancreatic cancer. The standard chemotherapy treatments that will be given in combination with AB680 and AB122 are nab-paclitaxel and gemcitabine. AB680 and AB122 are are not approved by the United States Food and Drug Administration (U.S. FDA).

Are you Eligible? (Inclusion Criteria)

  • Are you at least 18 years old?
  • Do you have histologically or cytologically confirmed metastatic pancreatic adenocarcinoma?
  • Are you naïve to any prior treatment, including chemotherapy, biological therapy, or targeted therapy for metastatic disease?

Specialty Area(s)

Pancreatic Cancer

Principal Investigator

Gulam A. Manji, MD

Profile Headshot
  • Director of Gastrointestinal Oncology
  • Director of Pancreas Translational Research
  • Co-Director of The Pancreas Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Open location in Google Maps